All In Biotech

NDA 205437 · Amgen INC

Otezla

Apremilast · Oral · Phosphodiesterase 4 Inhibitor

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 21, 2014

Approved uses

7

Original approval plus efficacy supplements

Registered trials

139

40 Phase 3, 12 recruiting

FAERS reports

146,435

35,036 serious, 6,208 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 2, 2026.

OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis ( 1.1 ) Plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Oral ulcers associated with Behçet's Disease ( 1.3 ) Pediatric patients 6 years of age and older with: Active psoriatic arthritis ( 1.1 ) Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) In the pediatric population, OTEZLA is indicated for patients weighing at least 20 kg, and OTEZLA XR is indicated for patients weighing at least 50 kg. 1.1 Psoriatic Arthritis OTEZLA is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis. OTEZLA XR is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis. 1.2 Plaque Psoriasis OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. OTEZLA XR is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.3 Oral Ulcers Associated with Behçet's Disease OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease.

Mechanism: Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • OTEZLA · APREMILAST 30MG · TABLET, ORAL · Prescription · TE AB
  • OTEZLA · APREMILAST 10MG · TABLET, ORAL · Prescription · TE AB
  • OTEZLA · APREMILAST 20MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Apremilast" as an intervention, any sponsor and status, largest first.

All 139 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea24,755
  • nausea22,292
  • psoriasis20,666
  • headache18,012
  • drug ineffective15,674
  • abdominal discomfort8,337
  • psoriatic arthropathy8,315
  • pain7,045
  • rash6,888
  • vomiting6,639
  • arthralgia6,531
  • fatigue6,327

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20123
20134
20141,244
201512,439
201613,932
201718,313
201819,926
201922,848
202019,781
202110,551
20227,338
20235,928
20246,024
20254,946
20263,158

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Otezla (Apremilast)

2024 spending

$1.05B

Beneficiaries

31,045

213,396 claims

Per beneficiary

$33,662

$80.68 per unit

View as table
YearSpending
2020$488,493,382
2021$582,336,333
2022$710,069,159
2023$876,955,030
2024$1,045,029,751

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 225 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.